Home / Market News / $ZEAL
fiscal.ai Corporate Catalyst Impact 85/100 ● positive

Zealand Pharma Receives EU Marketing Authorization for Zeydovio (glepaglutide)

Nov 13, 2026, 5:05 PM UTC · Primary ticker $ZEAL

Zealand Pharma announced that the European Commission has granted marketing authorization for Zeydovio (glepaglutide) for the treatment of adults with short bowel syndrome (SBS) across the EU and EFTA states. This approval is a significant milestone, representing the first major advancement in SBS treatment in over a decade, and positions the company for potential global commercialization.

Zealand Pharma has secured EU marketing authorization for Zeydovio, a long-acting GLP-2 analog for short bowel syndrome. This is a major positive catalyst as it's the first significant treatment advancement for SBS in over a decade, opening up a substantial market opportunity across Europe. This approval validates Zealand Pharma's drug development capabilities and provides a clear path to revenue generation in the short to medium term. For traders, this means potential upside for ZEAL as the company moves towards commercialization and partnership discussions, while also advancing its Phase 3 trial for US regulatory submission, indicating long-term growth potential. The key opportunity lies in the successful commercial launch and potential US approval.

$ZEAL positive EU marketing authorization for key drug
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.